SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549



                                    FORM 8-K
                                 CURRENT REPORT



     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934



          Date of Report (Date of earliest event reported) May 13, 2003



                         Progenics Pharmaceuticals, Inc.
             (Exact name of registrant as specified in its charter)



              Delaware              000-23143                 13-3379479
    (State or other jurisdiction    (Commission            (IRS Employer
         of incorporation)          File Number)        Identification No.)



             777 Old Saw Mill River Road, Tarrytown, New York   10591
               (Address of principal executive offices)      (Zip Code)


        Registrant's telephone number, including area code (914) 789-2800




         (Former name or former address, if changed since last report.)







Item 7.  Financial Statements and Exhibits

(c) Exhibits

         Exhibit 99.1      Description
                           Press Release dated May 13, 2003 (filed herewith).


Item 9. Regulation FD Disclosure.

         On May 13, 2003, Progenics Pharmaceuticals, Inc. issued a press release
announcing the initiation of a phase 2 clinical trial of its investigational
drug methylnaltrexone for the treatment of post-operative ileus, a paralysis of
the gastrointestinal tract that often occurs after surgery. The press release
also published new phase 1 clinical trial data that shows that methylnaltrexone
stimulates gastrointestinal mobility in absence of opioids. A copy of the press
release is attached as Exhibit 99.1.

         The information furnished pursuant to Item 9 in this Form 8-K shall not
be deemed to be "filed" for the purposes of Section 18 of the Securities
Exchange Act of 1934 or otherwise subject to the liabilities of that Section,
unless we specifically incorporate it by reference in a document filed under the
Securities Act of 1933 or the Securities Exchange Act of 1934. We undertake no
duty or obligation to publicly update or revise the information furnished
pursuant to Item 9 in this Form 8-K.









                                   SIGNATURES

                  Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                       PROGENICS PHARMACEUTICALS, INC.


                       By:  /s/ PHILIP K. YACHMETZ
                            -----------------------
                                Philip K. Yachmetz
                                Vice President, General Counsel and Secretary


Date:  May 13, 2003